Form 4: Provectus Biopharmaceuticals Director Edward Pershing Reports Conversion of Convertible Note into Preferred Stock

Director Edward Pershing reports the conversion of a convertible note into Series D-1 Preferred Stock and subsequent conversion of preferred stock into common stock.

Summary

• On March 17, 2024, Edward Pershing, a director of Provectus Biopharmaceuticals, reported transactions involving the company's securities.
• An 8% unsecured convertible promissory note was converted into 47,190 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• These 47,190 shares of Series D-1 Convertible Preferred Stock were then converted into 471,900 shares of Common Stock.
• Following these transactions, Pershing directly owns 1,093,762 shares of Provectus Biopharmaceuticals Common Stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• The original promissory note was issued pursuant to the Issuer's 2022 Financing.

Sentiment

Score: 5

Explanation: This is a routine filing reflecting a pre-arranged conversion of securities. It doesn't inherently indicate positive or negative sentiment, but rather a procedural update.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their beneficial ownership of company securities, providing transparency to investors.

Stakeholder Impact

• The conversion of preferred stock to common stock may slightly dilute existing shareholders' equity.

Key Dates